Synbiotic Dipeptide Composition for FODMAP-Free Butyrate Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for increasing colonic butyrate levels, such as prebiotics and probiotics, often cause unwanted side effects like diarrhea and flatulence, and there is a need for a more effective and patient-friendly approach to manage metabolic disorders like prediabetes and type 2 diabetes through modulation of satiety hormones.
Innovation Solution
A synbiotic composition comprising Bacillus subtilis strain and a dipeptide like L-Alanyl-L-Glutamine, potentially combined with plant extracts, is administered in enteric-coated capsules to enhance butyrate production and reduce satiety hormones like GLP-1 and PYY, thereby improving glucose metabolism and lipid profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If prebiotics (FODMAPs) are used to stimulate butyrate production, then butyrate levels increase, but unwanted side effects like diarrhea, abdominal pain, and flatulence occur
Solution Approach 1:
The patent changes the chemical parameter of the prebiotic substrate from FODMAP-containing carbohydrates to a FODMAP-free dipeptide (containing glutamine or glutamic acid). This parameter change allows stimulation of butyrate production by alternative bacterial pathways while avoiding the harmful fermentation effects of FODMAPs that cause diarrhea, abdominal pain, and flatulence.
Solution Approach 2:
The patent uses a simple dipeptide molecule as the prebiotic substrate, which is metabolically simpler and more directly utilized by butyrate-producing bacteria compared to complex FODMAP carbohydrates. This disposable, easily metabolizable substrate provides efficient butyrate production without the need for complex fermentation processes that generate harmful byproducts.
2Quantity of substance
If conventional prebiotic strategies are used, then butyrate production is stimulated, but applicability is limited in people with food intolerances or irritable bowel syndrome
Solution Approach 1:
The patent changes the substrate parameter from FODMAP carbohydrates to a FODMAP-free dipeptide, making the intervention universally applicable to all populations including those with food intolerances and irritable bowel syndrome. This parameter change removes the restriction that limited conventional prebiotics to only healthy individuals without gastrointestinal sensitivities.
Solution Approach 2:
The dipeptide-based synbiotic composition serves as a universal intervention that functions across diverse populations with different gastrointestinal tolerances. It maintains the primary function of stimulating butyrate production while adapting to the needs of vulnerable populations, achieving multi-functionality as both a therapeutic and preventive agent across different patient groups.
3Quantity of substance
If satiety hormones (GLP-1, PYY) are increased to manage weight, then weight control improves, but glucose metabolism and insulin sensitivity deteriorate
Solution Approach 1:
The patent inverts the conventional approach by reducing satiety hormones (GLP-1, PYY) rather than increasing them. This inversion achieves the surprising result of improving both weight control and glucose metabolism simultaneously, resolving the trade-off by demonstrating that lower satiety hormone levels can be beneficial when achieved through butyrate-mediated mechanisms rather than direct hormone administration.
Solution Approach 2:
The patent introduces butyrate as an intermediary substance that mediates between diet and hormone regulation. Butyrate acts as a signaling molecule that indirectly modulates satiety hormones and improves insulin sensitivity through epigenetic mechanisms and gut-brain axis communication, rather than directly administering hormones or their agonists, thus avoiding the metabolic side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synbiotic composition significantly increases fecal butyrate levels, reduces satiety hormones, and improves metabolic markers like fasting glucose and cholesterol levels, demonstrating efficacy in managing prediabetes and metabolic syndrome without adverse effects.
Implementation Method 1
The gut microbiota is a crucial modulator of health effects elicited by food components. The microbial metabolite butyrate has emerged as an important and targetable mediator of such effects
Implementation Method 2
A synbiotic composition comprising Bacillus subtilis strain and a dipeptide like L-Alanyl-L-Glutamine, potentially combined with plant extracts, is administered in enteric-coated capsules
Implementation Method 3
butyrate can trigger anti-inflammatory signaling via binding to arylhydrocarbon, GPR41, GPR109, and PPARĪ³ receptors
Implementation Method 4
The systemic actions of a sufficient butyrate supply can be summarized as a (beneficial) modulation of cardio-metabolic health (glucose and lipid metabolism leading to increased insulin sensitivity, reduced plasma glucose and cholesterol levels)
Data Source
AI summary
A synbiotic preparation contains at least one probiotic strain and at least one amino acid or derivative displaying an effect in glucose metabolism management, such as diabetes prevention or prediabetes treatment. The preparation modulates satiety hormones, such as CCK, GLP-1, and PYY. Methods are developed to treat obesity, adiposity, type 2 diabetes, and metabolic syndrome with the preparation. A preparation also decreases fasting glucose levels in a subject.